Loading...
XNYS
AORT
Market cap1.03bUSD
Oct 08, Last price  
21.21USD
1D
-1.85%
1Q
-11.96%
Jan 2017
10.76%
Name

Artivion Inc

Chart & performance

D1W1MN
XNYS:AORT chart
P/E
105.41
P/S
2.33
EPS
0.20
Div yield, %
—
Shrs. gr., 5y
4.49%
Rev. gr., 5y
11.75%
Revenues
441m
+13.59%
81,311,00094,763,000105,059,000111,685,000116,645,000119,626,000131,718,000140,763,000144,641,000145,898,000180,380,000189,702,000262,841,000276,222,000253,227,000298,836,000313,789,000354,004,000388,537,000441,330,000
Net income
10m
P
365,0007,201,00032,908,0008,679,0003,944,0007,371,0007,946,00016,172,0007,322,0004,005,00010,778,0003,704,000-3,805,0001,720,000-16,682,000-14,834,000-19,192,000-30,690,000-13,359,0009,768,000
CFO
38m
+71.48%
-1,071,0009,292,0009,537,00016,572,00020,837,00016,751,00018,990,00016,772,0008,118,00011,442,00019,719,00010,803,0009,881,00015,827,00012,369,000-2,585,000-5,153,00018,825,00022,236,00038,130,000
Dividend
Dec 09, 20150.03 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Related entities

Subsidiaries
JOTEC GmbH

Key people

James Mackin
Chairman of the Board, President, Chief Executive Officer, Director · since 2015
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Treasurer · since 2025
Jean Holloway
Senior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary · since 2016
Marshall Stanton
Senior Vice President, Clinical Research and Chief Medical Officer · since 2021
Florian Tyrs
Vice President - Global Operations · since 2023
Matthew Getz
Vice President - Human Resources · since 2019
Andrew Green
Vice President - Regulatory Affairs · since 2021
Amy Horton
Chief Accounting Officer, Vice President · since 2016
Rochelle Maney
Vice President - Global Quality · since 2021
John Davis
Senior Vice President - Global Sales and Marketing · since 2015
Thomas Ackerman
Independent Director · since 2003
Daniel Bevevino
Independent Director · since 2003
Marna Borgstrom
Independent Director · since 2018
James Bullock
Independent Director · since 2016
Elizabeth Hoff
Independent Director · since 2022
Independent Director · since 2012
Anthony Semedo
Independent Director · since 2021
IPO date
Feb 12, 1993
Employees
1,300
Domiciled in
US
Incorporated in
US
Legal address
C/O COGENCY GLOBAL INC.
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
Headquarters
1655 Roberts Blvd NW
Kennesaw, GA 30144
US
Previous name
CRYOLIFE, INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT